Yin et al. tested humanized IL-13Ra2 targeting second generation CAR-T cells in combination with different checkpoint blockades (anti-PD-1, anti-CTLA-4 and anti-TIM-3) in comparison with humanized epidermal growth factor receptor variant III (EGFRvIII) CAR-T cells in a glioma animal model. Here, IL13RA2 is linked to central nervous system cancer.